TICKERNOMICS Sign up
Last Update: 2024-12-27 15:26:01
Allogene Therapeutics Inc. ( ALLO ) https://www.allogene.com
2.17USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-33.64%
ALLO
SPY
32.66%
-85.92%
ALLO
SPY
108.59%
-91.76%
ALLO
SPY
302.52%
ALLO
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
391.18
192.14
2.86
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-1.38
3009.10
0.84
-39.49
0.00
-0.71
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-324686.36
-16563.64
-307806.82
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
9.0304
-99.62
-41.42
1.28
Other Earnings and Cash Flow Stats:
Allogene Therapeutics Inc. ( ALLO ) Net Income TTM ($MM) is -283.43
Allogene Therapeutics Inc. ( ALLO ) Operating Income TTM ($MM) is -284.57
Allogene Therapeutics Inc. ( ALLO ) Owners' Earnings Annual ($MM) is 0.00
Allogene Therapeutics Inc. ( ALLO ) Current Price to Owners' Earnings ratio is 0.00
Allogene Therapeutics Inc. ( ALLO ) EBITDA TTM ($MM) is -270.69
Allogene Therapeutics Inc. ( ALLO ) EBITDA Margin is -307806.82%
Capital Allocation:
Allogene Therapeutics Inc. ( ALLO ) has paid 0.00 dividends per share and bought back -41.539541 million shares in the past 12 months
Allogene Therapeutics Inc. ( ALLO ) has reduced its debt by 4.156 million USD in the last 12 months
Capital Structure:
Allogene Therapeutics Inc. ( ALLO ) Interest-bearing Debt ($MM) as of last quarter is 92
Allogene Therapeutics Inc. ( ALLO ) Annual Working Capital Investments ($MM) are 38
Allogene Therapeutics Inc. ( ALLO ) Book Value ($MM) as of last quarter is 463
Allogene Therapeutics Inc. ( ALLO ) Debt/Capital as of last quarter is 19%
Other Balance Sheet Stats:
Allogene Therapeutics Inc. ( ALLO ) has 51 million in cash on hand as of last quarter
Allogene Therapeutics Inc. ( ALLO ) has 32 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Allogene Therapeutics Inc. ( ALLO ) has 209 common shares outstanding as of last quarter
Allogene Therapeutics Inc. ( ALLO ) has 0 million USD of preferred stock value
Academic Scores:
Allogene Therapeutics Inc. ( ALLO ) Altman Z-Score is -3.35 as of last quarter
Allogene Therapeutics Inc. ( ALLO ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Allogene Therapeutics Inc. ( ALLO ) largest shareholder is owning shares at 0.00 ($MM) value
MESSEMER DEBORAH M.(an insider) Sold 9136 shares of Allogene Therapeutics Inc. ( ALLO ) for the amount of $19916.48 on 2024-12-09
17.42% of Allogene Therapeutics Inc. ( ALLO ) is held by insiders, and 80.20% is held by institutions
Allogene Therapeutics Inc. ( ALLO ) went public on 2018-10-11
Other Allogene Therapeutics Inc. ( ALLO ) financial metrics:
FCF:-217.94
Unlevered Free Cash Flow:-374.00
EPS:-1.27
Operating Margin:-324686.36
Gross Profit Margin:-16563.64
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-57.18
Beta:1.28
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Allogene Therapeutics Inc. ( ALLO ) :
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.